Dystrophie musculaire de Duchenne Dystrophie musculaire de Duchenne Dystrophie musculaire de Duchenne

Archives

Monthly Archive for: "September, 2020"
Sustained functional improvement with micro-dystrophin gene treatment
By Marie
In Research, Treatments
Posted 28 September 2020

Sustained functional improvement with micro-dystrophin gene treatment

Sarepta Therapeutics reports sustained functional improvement two years after treatment with SRP-9001, its investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy. [...]

Catabasis Newsletter – Communicating clinical trial results
By Marie
In News
Posted 18 September 2020

Catabasis Newsletter – Communicating clinical trial results

La Force is happy to share the latest edition of the Catabasis Connection newsletter – Communicating clinical trial results. Catabasis understands the importance of clearly communicating [...]

Worldwide rights of Vamorolone for DMD
By Marie
In News, Treatments
Posted 2 September 2020

Worldwide rights of Vamorolone for DMD

Santhera exercises option to obtain worldwide rights of Vamorolone for Duchenne muscular dystrophy (DMD) and All Other Indications La Force is happy to share this press release provided [...]

Virtual marathon for DMD
By Marie
In Testimonial
Posted 1 September 2020

Virtual marathon for DMD

Learning that your son has Duchenne muscular dystrophy (DMD) is watching your child lose his muscular ability month after month. This is Jean-Philippe Morand’s reality: his son Victor is [...]

Articles récents

  • The global day of giving
  • EMBARK, gene therapy for the treatment of DMD
  • Part B of MOMENTUM study of SRP-5051 in patients with DMD
  • World Duchenne Awareness Day 2021
  • ENDEAVOR, gene therapy for DMD

Catégories

  • Fundraising
  • in the Medias
  • News
  • Research
  • Testimonial
  • Treatments

+

Restez informé

    LA Force - Dystrophie musculaire de Duchenne

    La Force dmd - Tous droits réservés - Organisme de bienfaisance enregistré : 817683568RP0001
    La Force dmd La Force dmd
    • S’informer
      • Frequently Asked Questions
    • Make a Donation
    • Agir
      • Quick guige – Management of DMD
      • Take action – What’s your genetic profile?
      • Take action – Subscribe to registries
    • Aller plus loin
      • Go further – How can you access a new treatment?
      • Go further – How do researchers test new treatments?
      • Go further – How are drugs approved for use in Canada?
      • Go further – Who decides to reimburse drug costs?
    • Blog
    • About us
    • Contact-us
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistiques
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
    View preferences
    {title} {title} {title}